Bi-/multi-specific antibodies and fusion proteins offer significant advantages over traditional monoclonal antibodies, including enhanced therapeutic efficacy, broader target engagement, and improved pharmacokinetic profiles. However, their structural complexity, molecular heterogeneity, and diverse mechanisms of action introduce unique CMC challenges throughout development and commercialization.

Altruist Biologics has established a comprehensive development platform designed to address these complexities through advanced cell line development, process optimization, analytical characterization, and formulation expertise. Common challenges—including chain mispairing, aggregation, fragmentation, and complex potency assays—are addressed through optimized vector design, tailored purification strategies, in-depth characterization, and high-resolution analytical methods that support product quality, consistency, and regulatory readiness.

Key Takeaways:

• Gain insight into particle shedding behavior in peristaltic pumping and its potential implications for downstream operations.

• Review how operating conditions such as sterilization and backpressure influence pump life performance.

• Explore key material considerations for integrating TPE tubing into single-use systems, including weldability and system design constraints.